1. Home
  2. FLGT vs PHAT Comparison

FLGT vs PHAT Comparison

Compare FLGT & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fulgent Genetics Inc.

FLGT

Fulgent Genetics Inc.

HOLD

Current Price

$14.26

Market Cap

867.4M

Sector

Health Care

ML Signal

HOLD

Logo Phathom Pharmaceuticals Inc.

PHAT

Phathom Pharmaceuticals Inc.

HOLD

Current Price

$11.56

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FLGT
PHAT
Founded
2011
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
867.4M
1.0B
IPO Year
2016
2019

Fundamental Metrics

Financial Performance
Metric
FLGT
PHAT
Price
$14.26
$11.56
Analyst Decision
Buy
Strong Buy
Analyst Count
3
6
Target Price
$28.33
$19.50
AVG Volume (30 Days)
310.5K
898.5K
Earning Date
06-01-2026
05-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
42.72
EPS
N/A
N/A
Revenue
$18,730,000.00
$175,110,000.00
Revenue This Year
$12.64
$83.18
Revenue Next Year
$9.87
$61.43
P/E Ratio
N/A
N/A
Revenue Growth
N/A
216.93
52 Week Low
$14.57
$2.21
52 Week High
$31.04
$18.31

Technical Indicators

Market Signals
Indicator
FLGT
PHAT
Relative Strength Index (RSI) 15.95 39.53
Support Level N/A $10.65
Resistance Level $19.96 $12.77
Average True Range (ATR) 0.99 0.87
MACD -0.73 0.09
Stochastic Oscillator 2.02 14.01

Price Performance

Historical Comparison
FLGT
PHAT

About FLGT Fulgent Genetics Inc.

Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Share on Social Networks: